Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had its price objective lifted by investment analysts at Credit Suisse Group from $5.65 to $81.00 in a research note issued to investors on Thursday. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 73.34% from the stock’s previous close.

Several other brokerages also recently issued reports on SRPT. Barclays PLC assumed coverage on shares of Sarepta Therapeutics in a research note on Wednesday. They issued an “equal weight” rating for the company. Janney Montgomery Scott raised their price objective on shares of Sarepta Therapeutics from $65.00 to $73.00 and gave the stock a “fair value” rating in a research note on Monday, July 24th. Nomura reissued a “buy” rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. Robert W. Baird reissued an “outperform” rating and issued a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $62.33.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 46.73 on Thursday. The company’s market cap is $3.01 billion. The firm’s 50-day moving average price is $38.96 and its 200 day moving average price is $34.02. Sarepta Therapeutics has a 52 week low of $25.47 and a 52 week high of $63.73.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The firm’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.19) EPS. On average, equities research analysts forecast that Sarepta Therapeutics will post ($1.16) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Sarepta Therapeutics, Inc. (SRPT) Given New $81.00 Price Target at Credit Suisse Group” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/09/07/sarepta-therapeutics-inc-srpt-given-new-81-00-price-target-at-credit-suisse-group.html.

In other Sarepta Therapeutics news, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $410,000.00. Following the transaction, the director now directly owns 62,471 shares of the company’s stock, valued at $2,561,311. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas S. Ingram purchased 47,058 shares of the business’s stock in a transaction on Thursday, July 27th. The stock was purchased at an average cost of $42.50 per share, for a total transaction of $1,999,965.00. Following the completion of the acquisition, the chief executive officer now directly owns 382,058 shares of the company’s stock, valued at approximately $16,237,465. The disclosure for this purchase can be found here. Insiders sold 78,056 shares of company stock worth $3,224,208 over the last ninety days. Corporate insiders own 9.60% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Prentiss Smith & Co. Inc. grew its holdings in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new position in Sarepta Therapeutics in the first quarter worth $127,000. PNC Financial Services Group Inc. grew its holdings in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares during the last quarter. Finally, Edge Wealth Management LLC purchased a new position in Sarepta Therapeutics in the second quarter worth $175,000. 65.43% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.